Please use this identifier to cite or link to this item:
Title: Modulators of rituximab-induced complement-dependent cytotoxicity in diffuse large B-cell lymphoma
Authors: Ong, Charmaine Zi Yan
Keywords: Science::Biological sciences
Issue Date: 2021
Publisher: Nanyang Technological University
Source: Ong, C. Z. Y. (2021). Modulators of rituximab-induced complement-dependent cytotoxicity in diffuse large B-cell lymphoma. Final Year Project (FYP), Nanyang Technological University, Singapore.
Abstract: Rituximab, the chimeric monoclonal antibody targeting CD20, forms the cornerstone of therapy for diffuse large B-cell lymphoma (DLBCL). However, more than one-third of patients eventually become unresponsive or resistant to rituximab. Although the mechanisms of action and resistance are not well understood, it is postulated that complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity, and apoptosis mediates rituximab’s anti-tumor activity, of which CDC is commonly regarded as the main activity of rituximab in vitro. We investigated whether drugs often used in combination with rituximab affect CDC and discovered that etoposide, a chemotherapy drug, induces resistance in SU-DHL-4 cells. Using a robust rituximab-induced CDC assay, we performed a screen to identify compounds that might increase CDC when administered together with etoposide. It was found that combination with histone deacetylases (HDAC) and Chk1 inhibitors enhanced CDC in vitro. Most interestingly, preliminary data suggests that these compounds mediate CDC in a CD20-independent manner, which is uncommon among methods to overcome CDC resistance. In conclusion, etoposide induces resistance to CDC that is alleviated by HDAC and Chk1 inhibitors, possibly through a CD20-independent pathway. These results suggest the potential of HDAC and Chk1 inhibitors as candidate drugs to improve DLBCL treatment.
Fulltext Permission: restricted
Fulltext Availability: With Fulltext
Appears in Collections:SBS Student Reports (FYP/IA/PA/PI)

Files in This Item:
File Description SizeFormat 
CY4111 REPORT_U1740275L.pdf
  Restricted Access
3.44 MBAdobe PDFView/Open

Page view(s)

Updated on May 17, 2022


Updated on May 17, 2022

Google ScholarTM


Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.